Skip to content
value.today

AsclepiX Therapeutics, Inc.

🇺🇸 Baltimore, Maryland, USABiotechnologyFounded 2023
Total raised
$28 M
3 rounds on record
Latest round
$10 M
Jul 2023
First round on record
Oct 2018
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of AsclepiX Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2023$10 MNo. 3$10 to $50 million

AsclepiX Therapeutics, Inc.: Raise no. 3, Jul 2023

Investors in this round

9 investors had bought by the notice of Apr 26, 2024: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $13 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aleksander Popel · Executive Officer
  • Amir Shojaei · Executive Officer
  • Jill Tierney · Executive Officer
  • Niranjan Pandey · Executive Officer
  • Robert Dempsey · Executive Officer
  • Ben Askew · Director
  • Chris Garabedian · Director
  • Jordan Green · Director
  • Josh Barer · Director
  • Sapna Srivastava · Director
  • Steven Altschuler · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Dempsey, Chief Executive Officer. Newest notice filed Apr 26, 2024. Read the notice at the SEC.

equitySEC
May 2020$10 MNo. 2$10 to $50 million

AsclepiX Therapeutics, Inc.: Raise no. 2, May 2020

Investors in this round

34 investors had bought by the notice of Jun 11, 2020: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $35 M offered; $25 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Kevin S. Slawin, MD · Executive Officer, Director
  • Aleksander S. Popel, PhD · Director
  • Jordan J. Green · Director
  • Joshua S. Barer · Director
  • Sapna S. Srivastava · Director
  • Steven S. Altschuler, MD · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kevin Slawin, M.D., Interim Chief Executive Officer. Newest notice filed Jun 11, 2020. Read the notice at the SEC.

equitySEC
Oct 2018$8 MNo. 1$2 to $10 million

AsclepiX Therapeutics, Inc.: Raise no. 1, Oct 2018

Investors in this round

26 investors had bought by the notice of Jun 17, 2019: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $10 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$40,000
Finders' fees
none
Paid to its own people
$575,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Wendy Perrow · Executive Officer, Director
  • Aleksander S. Popel, PhD · Director
  • Jordan J. Green · Director
  • Joshua S. Barer · Director
  • Kevin S. Slawin, MD · Director
  • Sapna S. Srivastava · Director
  • Steven S. Altschuler, MD · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Solebury Capital LLC (CRD 143299) · New Hope, PennsylvaniaSold in FL

Signed by Wendy Perrow, Chief Executive Officer. Newest notice filed Jun 17, 2019 (1 amendment). Read the notice at the SEC.

debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • AsclepiX Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2024).

    SEC Form D · Apr 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of AsclepiX Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by AsclepiX Therapeutics, Inc.
NameRoleNamed in
Aleksander PopelExecutive officerApr 2024
Amir ShojaeiExecutive officerApr 2024
Jill TierneyExecutive officerApr 2024
Niranjan PandeyExecutive officerApr 2024
Robert DempseyExecutive officerApr 2024
Kevin S. Slawin, MDExecutive officerJun 2020
Wendy PerrowExecutive officerJun 2019
Ben AskewDirectorApr 2024
Chris GarabedianDirectorApr 2024
Jordan GreenDirectorApr 2024
Josh BarerDirectorApr 2024
Sapna SrivastavaDirectorApr 2024
Steven AltschulerDirectorApr 2024
Aleksander S. Popel, PhDDirectorJun 2020
Jordan J. GreenDirectorJun 2020
Joshua S. BarerDirectorJun 2020
Kevin S. Slawin, MDDirectorJun 2020
Sapna S. SrivastavaDirectorJun 2020
Steven S. Altschuler, MDDirectorJun 2020
Wendy PerrowDirectorJun 2019
Aleksander Popel, PhDDirectorOct 2018
Joshua BarerDirectorOct 2018
Kevin Slawin, MDDirectorOct 2018